Blackthorn Therapeutics Stock | BioTech | Founded: 2015 | Funding to Date: $130,300,000

Operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.


Management Team
  • William Martin Ph.D - Co-Founder, President, Chief Executive Officer & Board Member
  • Monique Levy - Chief Strategy Officer
  • Edward Roberts Ph.D - Scientific Co-Founder
  • Jane Tiller MD - Chief Medical Officer
  • Hugh Rosen Ph.D - Scientific Co-Founder
  • Paul Berns - Executive Chairman
Board Members
  • Asish Xavier Ph.D - Johnson & Johnson Innovation - JJDC
  • Brian Chee - Polaris Partners
  • John MacPhee -
  • Julie Sunderland - Biomatics Capital
  • Kristina Burow - ARCH Venture Partners
  • Lori Hu - Vertex Ventures HC
  • Matthew Fust -
  • Paul Berns -
  • William Martin Ph.D -


Private Growth Index